InMed Pharmaceuticals (INM) Non-Current Deferred Tax Liability (2022 - 2025)

InMed Pharmaceuticals has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $20000.0 in Q2 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $20000.0 in Q2 2025; TTM through Jun 2025 was $20000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $20000.0, changed N/A from the prior year.
• Non-Current Deferred Tax Liability was $20000.0 for Q2 2025 at InMed Pharmaceuticals, down from $211266.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $211266.0 in Q2 2023, with the low at $20000.0 in Q2 2025.
• Average Non-Current Deferred Tax Liability over 3 years is $101024.0, with a median of $71806.0 recorded in 2022.
• The largest YoY upside for Non-Current Deferred Tax Liability was 194.22% in 2023 against a maximum downside of 194.22% in 2023.
• Over 3 years, Non-Current Deferred Tax Liability stood at $71806.0 in 2022, then surged by 194.22% to $211266.0 in 2023, then sank by 90.53% to $20000.0 in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $20000.0 (Q2 2025), $211266.0 (Q2 2023), and $71806.0 (Q2 2022), per Business Quant data.